Flexipharm Austrading Limited

Information

Name

Type

Company

Roles

Supplier

Company Size

Sme

Company Number

Incorporation Date

Website

Address

Bourne End

United Kingdom

Suppliers

Unlock the full supplier list, free!

Sign up to unlock the full list of suppliers associated with Flexipharm Austrading Limited
Sign up free

Contracts awarded to Flexipharm Austrading Limited

The contracts that Flexipharm Austrading Limited have been awarded to supply. Click on the contract to view more detailed information and view the full details about the contract won.

Award

Published 2 months ago

NHS National Generic Pharmaceuticals Wave 15b

NHS National Pharmaceuticals Generic Products – Wave 15b Offer reference number: CM/PHG/23/5698 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: CM/PHG/23/5698/01 – Orals (plus non-parenteral) Products CESW: (Midlands and Southwest): 1st October 2025 to 31st May 2027 (20 months) NWLN: (Northwest and London North): 1st October 2025 to 31st May 2027 (20 months) LSNE: (London South and Northeast): 1st October 2025 to 31st May 2027 (20 months) CM/PHG/23/5698/02 – Hospital Only Products DCE (Midlands) & DSW (Southwest): 1st October 2025 to 30th September 2027 (24 months) CM/PHG/23/5698/03 – Hospital Only (Housekeeping) Products DLS (London South) & DNE (Northeast): 1st October 2025 to 31st May 2026 (8 months) DNW (Northwest) & DLN (London North): 1st October 2025 to 31st January 2027 (16 months) DCE (Midlands) & DSW (Southwest): 1st October 2025 to 31st May 2026 (8 months)

£147
Award

Published 8 months ago

NP39724 Generic and Biosimilar Cancer Medicines

Supply of Generic and Biosimilar Cancer Medicines to NHS Scotland.

£10,396,962
Award

Published 10 months ago

NHS National Generic Pharmaceuticals Wave 15a

NHS National Generic Pharmaceuticals - Wave 15a. Offer reference number: CM/PHG/23/5697. Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: CM/PHG/23/5697/01 – Orals (plus non-parenteral) Products: All Regions (CESW/LSNE/NWLN): 01/02/2025 to 31/05/2027 (28 Months) CM/PHG/23/5697/02 – Hospital Only Products: DNW & DLN: 01/02/2025 to 31/01/2027 (24 months) CM/PHG/23/5697/03 – Hospital Only Products (Housekeeping): DLS & DNE: 01/02/2025 to 31/05/2026 (16 months) DCE & DSW: 01/02/2025 to 30/09/2025 (8 months)

£170

Contacts

+44 7763329345

Statistics (1 Year)

Contracts Won

Total Won

£10,396,962

Average Win

£10,396,962

Flexipharm Austrading Limited

Information

Name

Type

Roles

Company Size

Company Number

Incorporation Date

Website

Address

Suppliers

Contracts awarded to Flexipharm Austrading Limited

NHS National Generic Pharmaceuticals Wave 15b

NP39724 Generic and Biosimilar Cancer Medicines

NHS National Generic Pharmaceuticals Wave 15a

Contacts

Statistics (1 Year)

Contracts Won

Total Won

Average Win